# **PRODUCT** INFORMATION



VU590 (hydrochloride)

Item No. 15177

CAS Registry No.:	1783987-83-6		
Formal Name:	7,13-bis(4-nitrobenzyl)-1,4,10-		
	trioxa-7,13-diazacyclopentadecane,	,	
	dihydrochloride	$O_2N \longrightarrow O_2N \longrightarrow $	$\langle \rangle - NO_2$
Synonyms:	CID-4536383, ML-111		
MF:	C <sub>24</sub> H <sub>32</sub> N <sub>4</sub> O <sub>7</sub> • 2HCl		
FW:	561.5		
Purity:	≥98%	$\sim$	
UV/Vis.:	λ <sub>max</sub> : 259, 350 nm		
Supplied as:	A crystalline solid	• 2HCl	
Storage:	-20°C		
Stability:	≥4 years		
Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis			

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

## Laboratory Procedures

VU590 (hydrochloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the VU590 (hydrochloride) in the solvent of choice, which should be purged with an inert gas. VU590 (hydrochloride) is soluble in the organic solvent DMSO. It is also soluble in water. The solubility of VU590 (hydrochloride) in DMSO and water is approximately 20 and 10 mg/ml, respectively. We do not recommend storing the aqueous solution for more than one day.

## Description

KCNJ1 (K<sub>ir</sub>1.1, or renal outer medullary potassium channel) and KCNJ13 (K<sub>ir</sub>7.1) are inwardly rectifying two-transmembrane K<sup>+</sup> channels. KCNJ1 has critical roles in kidney function, while KCNJ13 is important in the eye, kidney, and small intestine.<sup>1,2</sup> VU590 is a small molecule inhibitor of KCNJ1 (IC<sub>50</sub> = 294 nM) which also causes 70% inhibition of KCNJ13 at 10  $\mu$ M.<sup>3</sup> It has no effect on the related channels KCNJ2 (K, 2.1) and KCNJ10 (K<sub>i</sub>, 4.1) at a concentration of 10  $\mu$ M.<sup>3</sup>

## References

- 1. Hebert, S.C., Desir, G., Giebisch, G., et al. Molecular diversity and regulation of renal potassium channels. Physiol. Rev. 85(1), 319-371 (2005).
- 2. Edwards, A.O. Clinical features of the congenital vitreoretinopathies. Eye (Lond) 22(10), 1233-1242 (2008).
- 3. Denton, J.S., Weaver, C.D., Lewis, L.M., et al. Discovery of a small molecule inhibitor of ROMK and K. 7.1, in Probe Reports from the NIH Molecular Libraries Program,1 (2009).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

### SAFETY DATA

SAFETY DATA This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/15/2022

## CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM